Pioneering New Drug Modalities: The Future of Therapeutic Leadership

Discover an informative webinar focusing on the transformative potential of multimodal drug discovery in shaping the future of therapeutic leadership. As the pharmaceutical and biotechnology landscape rapidly evolves, embracing diverse strategies and harnessing the power of new drug modalities has become essential for developing groundbreaking treatments.

In this webinar, the speakers will share insights into the diverse and dynamic world of new drug modalities, including their classification based on therapeutic mechanics and stages of development, and their projected impact on the industry. They will also discuss strategic considerations for companies navigating this dynamic field such as resource allocation, risk management and leveraging collaborative ecosystems.

They will also delve into the critical role of data-driven strategies and modern software solutions, focusing on capturing, structuring and analyzing vast amounts of data, as well as streamlining processes and facilitating decision-making. They will examine how the future of drug discovery is being shaped by technological advancements and scientific breakthroughs, particularly through artificial intelligence (AI), machine learning (ML) and transformative collaborative ecosystems.

They will also highlight how Revvity Signals’ cutting-edge solutions, such as the Signals Research Suite, can support and accelerate multimodal drug discovery efforts by providing tools that facilitate collaboration, streamline data management and empower scientists.

Register for this webinar today to gain insights into the impact of new drug modalities, strategic considerations for navigating the drug discovery field and the role of data-driven strategies.

Speaker

Zev Wisotsky, Director of Drug Discovery Informatics, Revvity Signals

Zev Wisotsky is Director of Drug Discovery Informatics at Revvity Signals. His scientific training and research background includes neuroscience, biochemistry, molecular biology and drug discovery. He has spent over eight years in software in go-to-market teams across industries with a heavy focus on biopharma/biotech R&D.

Message Presenter